Skip to main content

Table 1 LCT detection results distribution

From: HPV-specific risk assessment of cervical cytological abnormalities

  

normal

AGC

ASC-H

ASC-US

LSIL

HSIL

SCC

HPV status

N

1745 (78.5%)

8 (0.4%)

26 (1.2%)

264 (11.9%)

152 (6.8%)

23 (1.0%)

6 (0.3%)

Age

37.9 ± 9.1

39.4 ± 14.5

40.1 ± 9.1

35.0 ± 9.2

36.6 ± 9.4

41.1 ± 7.8

44.8 ± 14.2

HPV infection

359 (20.6%)

3 (37.5%)

19 (73.1%)

159 (60.2%)

127 (83.6%)

17 (73.9%)

4 (66.7%)

HR-HPV infection

318 (18.2%)

3 (37.5%)

19 (73.1%)

140 (53.0%)

119 (78.3%)

16 (69.6%)

4 (66.7%)

LR-HPV infection

60 (3.4%)

0 (0.0%)

3 (11.5%)

33 (12.5%)

15 (9.9%)

1 (4.3%)

0 (0.0%)

HR + LR infection

19 (1.1%)

0 (0.0%)

3 (11.5%)

14 (5.3%)

7 (4.6%)

0 (0.0%)

0 (0.0%)

Multiple HR-HPV infection

57 (3.3%)

0 (0.0%)

1 (3.8%)

33 (12.5%)

42 (27.6%)

2 (8.7%)

0 (0.0%)

Symptoms

Post-coital bleeding

238 (13.6%)

1 (12.5%)

5 (19.2%)

37 (14.0%)

30 (19.7%)

1 (4.3%)

1 (16.7%)

Postmenopausal bleeding

493 (28.3%)

2 (25.0%)

3 (11.5%)

87 (33.0%)

51 (33.6%)

5 (21.7%)

2 (33.3%)

Last Abnormal LCT

136 (7.8%)

2 (25.0%)

1 (3.8%)

29 (11.0%)

10 (6.6%)

0 (0.0%)

0 (0.0%)

Abnormal menstruation

444 (25.4%)

1 (12.5%)

7 (26.9%)

67 (25.4%)

41 (27.0%)

7 (30.4%)

1 (16.7%)

Irregular bleeding

72 (4.1%)

0 (0.0%)

1 (3.8%)

10 (3.8%)

9 (5.9%)

0 (0.0%)

0 (0.0%)

Uterine prolapse

158 (9.1%)

1 (12.5%)

3 (11.5%)

26 (9.8%)

12 (7.9%)

5 (21.7%)

0 (0.0%)

Others

589 (33.8%)

3 (37.5%)

13 (50.0%)

82 (31.1%)

42 (27.6%)

10 (43.5%)

2 (33.3%)

  1. LCT Liquid-based cytology test
  2. HR-HPV High-risk HPV
  3. LR-HPV Low-risk HPV